Rapha Capital Management Announces Successful Initial Public Offering of Portfolio Company NexImmune Inc.
Rapha Capital Management announced that its portfolio company, NexImmune, Inc., successfully closed an upsized initial public offering on February 17, 2021, raising approximately $126.5 million. The IPO's proceeds included the full exercise of the underwriters' option to purchase additional shares. Rapha Capital Investment II, LLC, had earlier invested $1.8 million in NexImmune through its Series A and A-2 financing rounds. NexImmune trades on the Nasdaq under the symbol NEXI and focuses on developing innovative immunotherapy solutions.
- NexImmune raised gross proceeds of $126.5 million through its IPO.
- Successful upsizing of the IPO indicates strong investor interest.
- Previous investment of $1.8 million by Rapha Capital reflects confidence in NexImmune's potential.
- None.
MIAMI, Feb. 24, 2021 /PRNewswire/ -- Rapha Capital Management, LLC (https://raphacap.com), an investment management firm located in Miami, Florida, is pleased to announce that on February 17, 2021, its portfolio company, NexImmune, Inc. ("NexImmune"), closed an upsized initial public offering raising gross proceeds, before deducting underwriting discounts and commissions and offering expenses, of approximately
Rapha Capital Management is an investment management firm focused on managing strategic investments in early stage, non-public biotechnology companies, through special purpose investment vehicles ("SPIVs"). Rapha Capital was founded by its President, Kevin Slawin, M.D., a successful and experienced oncologic and robotic surgeon. After leaving practice, Dr. Slawin has been serving as a biotech consultant, investor, and founder, focusing on disruptive technologies in oncology, T cells and immunotherapy, and other breakthrough healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc. ("Bellicum"), a publicly traded company listed on NASDAQ, leading Bellicum to a successful
"We recognized the transformative potential of immunotherapy early on, founding Bellicum Pharmaceuticals, one of the first cellular immunotherapy companies in 2004, and have been an expert in identifying other potentially disruptive technologies, since 2017, when Rapha Capital Management was founded," commented Kevin Slawin, MD. "RCI II's investment in NexImmune is another example of our commitment to use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples' lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities," he added.
About NexImmune, Inc.
NexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent and durable immune response that mimics natural biology. NexImmune's IPO pricing announcement can be accessed here.
About Rapha Capital Management, LLC
Rapha Capital Management, LLC is an investment management firm located in Miami, Florida, focusing on identifying and managing strategic investments in early stage, non-public biotechnology companies. Rapha Capital was founded by its President, Kevin Slawin, MD, a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc., a publicly traded company listed on NASDAQ. He is co-Inventor of the FDA,-approved "prostate health index (phi)" test licensed and marketed by Beckman Coulter and utilized around the world. He has published extensively in top medical and scientific journals including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM). He has also been routinely listed in America's Top Doctors for Cancer (Castle Connolly Medical) and The Best Doctors in America (Woodward/White). In 2003, he was awarded the F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology.
For more information email info@raphacapital.com or visit https://www.raphacap.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/rapha-capital-management-announces-successful-initial-public-offering-of-portfolio-company-neximmune-inc-301234097.html
SOURCE Rapha Capital Management, LLC
FAQ
What was the IPO amount raised by NexImmune on February 17, 2021?
What is the stock symbol for NexImmune?
How much did Rapha Capital invest in NexImmune?
What was the purpose of NexImmune's IPO?
